Among dietary flavonoids studied as senolytics, compounds that selectively clear senescent "zombie" cells, fisetin has the most active human clinical trial program currently underway, including studies on vascular function in older adults. Apigenin is studied alongside it for related anti-inflammatory and senescence-related properties, though with a smaller trial base specifically for this application. This guide covers what the evidence supports today, honestly, rather than overselling an early-stage field.
Quick Facts
- Most active human trial program: Fisetin
- Complementary compound: Apigenin
- Prescription combination (not a supplement): Dasatinib plus quercetin, physician-supervised only
- Key nuance: Benefit may be concentrated in those with a confirmed senescent cell burden
- Overall field status: More than 30 clinical trials ongoing or planned, still an early-stage field
Fisetin: The Most Actively Studied Dietary Senolytic
Fisetin, a flavonoid found in strawberries and other fruits, is under active investigation in multiple ongoing human trials, including a pilot study on vascular endothelial function and aortic stiffness in older adults. It's worth noting that an earlier, different senolytic compound (UBX0101, not fisetin) failed in a Phase II osteoarthritis trial, a useful reminder that senolytic promise in preclinical research doesn't automatically translate to clinical success, and that fisetin's own human outcome data is still accumulating. See our full Fisetin guide.
Apigenin: A Complementary Candidate
Apigenin, found in chamomile and parsley among other plants, shares some structural and mechanistic similarities with fisetin and is studied for related anti-inflammatory and cellular effects, though it has a smaller dedicated senolytic trial base specifically. See our full Apigenin guide.
Why Prescription Senolytics Are a Different Category
The dasatinib plus quercetin combination, the most-studied senolytic protocol in early human trials, involves dasatinib, a prescription cancer medication, and is not an over-the-counter supplement strategy. A 2024 Phase 2 trial of this combination in postmenopausal women found bone health benefits concentrated specifically in those with a larger existing senescent cell burden, an important finding for the whole senolytic field, not just this combination.
What the Research Actually Shows
Targeted response in people with senescent burden. Evidence level: Promising, population-specific. The strongest human signal so far suggests benefit is concentrated in people who actually have a measurable, elevated senescent cell burden, not a universal effect.
Fisetin's standalone human outcome data. Evidence level: Early-stage. Multiple trials are underway, but as of this writing, large, confirmatory outcome trials specifically for fisetin alone are still in progress rather than completed and widely replicated.
Dosage & Timing
Fisetin research often uses an "intermittent" or "hit-and-run" dosing strategy, higher doses taken for a few consecutive days periodically, rather than continuous daily use, based on the theory that senolytics need only transiently trigger senescent cell death rather than being present in the body at all times. This dosing pattern differs meaningfully from most other supplements discussed on this site and reflects the specific, distinct mechanism senolytics are believed to work through.
Safety & Who Should Be Cautious
Fisetin and apigenin have generally favorable safety profiles as dietary flavonoids at studied doses. The dasatinib-quercetin protocol should only be used under direct medical supervision given dasatinib's prescription status and side effect profile. Anyone considering intermittent, high-dose senolytic protocols should discuss this specifically with a healthcare provider given the departure from standard continuous-use supplement dosing.
ⓘ Fisetin has the most active human research program among dietary senolytics, but the field overall is still early-stage, and benefit appears concentrated in people who actually have a meaningful senescent cell burden.
Frequently Asked Questions
What is the best senolytic supplement?
Fisetin currently has the most active human clinical trial program among dietary senolytic candidates, though the overall field is still early-stage.
Why is fisetin dosed differently than other supplements?
Research often uses an intermittent, "hit-and-run" dosing strategy rather than continuous daily use, based on the theory that senolytics need only transiently trigger senescent cell clearance.
Is dasatinib plus quercetin something I can take over the counter?
No, dasatinib is a prescription medication and this combination should only be used under direct medical supervision, not as a self-directed supplement protocol.
Do senolytics work for young, healthy people?
Available evidence suggests benefit may be concentrated in people with a meaningful, existing senescent cell burden, which tends to increase with age, so the case for younger, healthy individuals is less established.
How many clinical trials are studying senolytics right now?
More than 30 senolytic clinical trials are planned, ongoing, or completed across various compounds and conditions, reflecting substantial current research interest in this field.
Scientific References
- "Results from a Phase 2 Trial of Senolytic Therapy Dasatinib and Quercetin for Osteoporosis." Clinical trial report, 2024.
- "Fisetin to Improve Vascular Function in Older Adults." ClinicalTrials.gov, NCT06133634.
Disclaimer
This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It does not constitute medical advice and is independent of any specific product or brand. Always consult a qualified healthcare provider before beginning any new supplement regimen, particularly senolytic protocols with non-standard dosing patterns.
